MYOV- NYSE (USA) Also traded in: Germany
Myovant Sciences Ltd

Not Rated

Top Ranked Predictable Companies

$10.46

0.56(5.66%) Volume: 704,426 10:08PM EDT

Avg Vol (1m): 914,326

Warning! GuruFocus has detected 7 Severe Warning Signs with NYSE:MYOV. Click here to check it out.

Market Cap : 997.17 M	Enterprise Value : 877.49 M	PE Ratio : At Loss	PB Ratio :

RSS

Manual of Stocks™ Web APP

Manual of Stocks™

Sorry. Only PremiumPlus Member can access this feature.

Free Trial

Switch to:

中文

Fundamental
- 5-Year EBITDA Growth Rate
- Altman Z-Score
- Beneish M-Score
- Book Value per Share
- Cash per Share
- Dividends per Share
- E10
- Earnings per Share (Diluted)
- EBIT per Share
- EBITDA per Share
- Enterprise Value
- EPS without NRI
- FFO per Share
- Financial Strength
- Float Percentage Of Total Shares Outstanding
- Free Cash Flow per Share
- GF Score
- GF Value Rank
- Growth Rank
- Insider Ownership
- Institutional Ownership
- Market Cap
- Momentum Rank
- Net Cash per Share
- Net Current Asset Value
- Net-Net Working Capital
- Operating Cash Flow per Share
- Owner Earnings per Share (TTM)
- Piotroski F-Score
- Predictability Rank
- Probability of Financial Distress (%)
- Profitability Rank
- Quality Rank
- Revenue per Share
- Scaled Net Operating Assets
- Short Interest
- Short Percentage of Float
- Tangible Book per Share
- Total Debt per Share
- Valuation Rank
- YoY EBITDA Growth
- YoY EPS Growth
- YoY Rev. per Sh. Growth
Valuation Ratio
- Asset Turnover
- Buyback Yield %
- Capex-to-Operating-Cash-Flow
- Capex-to-Operating-Income
- Capex-to-Revenue
- Cash Conversion Cycle
- Cash Ratio
- Cash-to-Debt
- COGS-to-Revenue
- Current Ratio
- Days Inventory
- Days Payable
- Days Sales Outstanding
- Debt-to-Asset
- Debt-to-EBITDA
- Debt-to-Equity
- Debt-to-Revenue
- Earnings Yield %
- Earnings Yield (Joel Greenblatt) %
- Effective Interest Rate on Debt %
- Equity-to-Asset
- EV-to-EBIT
- EV-to-EBITDA
- EV-to-FCF
- EV-to-Revenue
- Forward PE Ratio
- Forward Rate of Return (Yacktman) %
- Goodwill-to-Asset
- Gross-Profit-to-Asset %
- Interest Coverage
- Inventory Turnover
- Inventory-to-Revenue
- Liabilities-to-Assets
- LT-Debt-to-Total-Asset
- PB Ratio
- PE Ratio
- PE Ratio
- PE Ratio without NRI
- PEG Ratio
- Price-to-Free-Cash-Flow
- Price-to-Funds-From-Operations
- Price-to-Operating-Cash-Flow
- Price-to-Owner-Earnings
- Price-to-Tangible-Book
- PS Ratio
- Quick Ratio
- Return-on-Tangible-Asset
- Return-on-Tangible-Equity
- ROA %
- ROC %
- ROC (Joel Greenblatt) %
- ROCE %
- ROE %
- ROE % Adjusted to Book Value
- ROIC %
- Shares Buyback Ratio %
- Shiller PE Ratio
- Short Ratio
- Sloan Ratio %
- Total Payout Ratio
- Total Payout Yield %
- WACC %
Profitability
- EBITDA Margin %
- FCF Margin %
- Gross Margin %
- Net Interest Margin (Bank Only) %
- Net Margin %
- Operating Margin %
Price
- Beta
- Earnings Power Value (EPV)
- GF Value
- Graham Number
- Intrinsic Value: DCF (Earnings Based)
- Intrinsic Value: DCF (FCF Based)
- Intrinsic Value: Projected FCF
- Margin of Safety % (DCF Earnings Based)
- Median PS Value
- Peter Lynch Fair Value
- Volatility
Dividends
- 3-Year Dividend Growth Rate
- 5-Year Dividend Growth Rate
- 5-Year Yield-on-Cost %
- Dividend Payout Ratio
- Dividend Yield %
- Dividend-Payout-to-FFO
- Forward Dividend Yield %
Income Statement
- Cost of Goods Sold
- Credit Losses Provision
- Depreciation, Depletion and Amortization
- EBIT
- EBITDA
- EPS (Basic)
- EPS (Diluted)
- Fees and Other Income
- Gross Profit
- Interest Expense
- Interest Expense (Positive)
- Interest Income
- Net Income
- Net Income (Continuing Operations)
- Net Income (Discontinued Operations)
- Net Interest Income
- Net Interest Income (for Banks)
- Net Investment Income
- Net Policyholder Benefits/Claims
- Non Interest Income
- Non Operating Income
- Operating Income
- Other Expense
- Other Income (Expense)
- Other Income (Minority Interest)
- Other Noninterest Expense
- Other Operating Expense
- Policy Acquisition Expense
- Pre-Tax Income
- Preferred Dividends
- Research & Development
- Revenue
- Selling, General, & Admin. Expense
- Shares Outstanding (Basic Average)
- Shares Outstanding (Diluted Average)
- SpecialCharges
- Tax Expense
- Tax Provision
- Tax Rate %
- Total Expenses
- Total Noninterest Expense
- Total Operating Expense
- Total Premiums Earned
Balance Sheet
- Accounts Payable
- Accounts Payable & Accrued Expense
- Accounts Payable & Accrued Expense for Financial Companies
- Accounts Receivable
- Accumulated Depreciation
- Accumulated other comprehensive income (loss)
- Additional Paid-In Capital
- Allowance For Loans And Lease Losses
- Buildings And Improvements
- Cash And Cash Equivalents
- Cash and cash equivalents
- Cash, Cash Equivalents, Marketable Securities
- Common Stock
- Construction In Progress
- Current Accrued Expense
- Current Deferred Revenue
- Current Deferred Taxes Liabilities
- Deferred Policy Acquisition Costs
- DeferredTaxAndRevenue
- Equity Investments
- Fixed Maturity Investment
- Future Policy Benefits
- Goodwill
- Gross Loan
- Gross Property, Plant and Equipment
- Intangible Assets
- Inventories, Finished Goods
- Inventories, Inventories Adjustments
- Inventories, Other
- Inventories, Raw Materials & Components
- Inventories, Work In Process
- Investments And Advances
- Land And Improvements
- Loans Receivable
- Long-Term Capital Lease Obligation
- Long-Term Debt
- Long-Term Debt & Capital Lease Obligation
- Machinery, Furniture, Equipment
- Marketable Securities
- Minority Interest
- Money Market Investments
- Net Loan
- NonCurrent Deferred Liabilities
- Notes Receivable
- Other Assets for Banks
- Other Assets for Insurance Companies
- Other Current Assets
- Other Current Liabilities
- Other Current Payables
- Other Current Receivables
- Other Gross PPE
- Other Liabilities for Banks
- Other Liabilities for Insurance Companies
- Other Long Term Assets
- Other Long-Term Liabilities
- Other Stockholders Equity
- PensionAndRetirementBenefit
- Policyholder Funds
- Preferred Stock
- Property, Plant and Equipment
- Retained Earnings
- Securities & Investments
- Shares Outstanding (EOP)
- Short-Term Capital Lease Obligation
- Short-Term Debt
- Short-Term Debt & Capital Lease Obligation
- Short-term investments
- Total Assets
- Total Current Assets
- Total Current Liabilities
- Total Deposits
- Total Equity
- Total Inventories
- Total Liabilities
- Total Long-Term Assets
- Total Long-Term Liabilities
- Total Receivables
- Total Stockholders Equity
- Total Tax Payable
- Treasury Stock
- Unearned Income
- Unearned Premiums
- Unpaid Loss & Loss Reserve
Cashflow Statement
- All Taxes Paid
- Asset Impairment Charge
- Beginning Cash Position
- Capital Expenditure
- Cash Flow for Dividends
- Cash Flow from Discontinued Operations
- Cash Flow from Financing
- Cash Flow from Investing
- Cash Flow from Operations
- Cash Flow from Others
- Cash From Discontinued Investing Activities
- Cash from Discontinued Operating Activities
- Cash From Other Investing Activities
- Cash Paid for Insurance Activities
- Cash Payments
- Cash Payments for Deposits by Banks and Customers
- Cash Payments for Loans
- Cash Receipts from Deposits by Banks and Customers
- Cash Receipts from Fees and Commissions
- Cash Receipts from Loans
- Cash Receipts from Operating Activities
- Cash Receipts from Securities Related Activities
- Cash Receipts from Tax Refunds
- Cash Received from Insurance Activities
- Change In Inventory
- Change In Other Working Capital
- Change In Payables And Accrued Expense
- Change In Prepaid Assets
- Change In Receivables
- Change In Working Capital
- Deferred Tax
- Depreciation, Depletion and Amortization
- Dividends Paid
- Dividends Received
- Effect of Exchange Rate Changes
- Ending Cash Position
- FFO
- Free Cash Flow
- Interest and Commission Paid
- Interest Paid
- Interest Received
- Issuance of Debt
- Issuance of Stock
- Net Change in Cash
- Net Income From Continuing Operations
- Net Intangibles Purchase And Sale
- Net Issuance of Debt
- Net Issuance of Preferred Stock
- Other Cash Payments from Operating Activities
- Other Cash Receipts from Operating Activities
- Other Financing
- Payments of Debt
- Payments on Behalf of Employees
- Payments to Suppliers for Goods and Services
- Purchase Of Business
- Purchase Of Investment
- Purchase Of Property, Plant, Equipment
- Receipts from Customers
- Receipts from Government Grants
- Repurchase of Stock
- Sale Of Business
- Sale Of Investment
- Sale Of Property, Plant, Equipment
- Stock Based Compensation
- Taxes Refund Paid
Technical Indicator
- 5-Day RSI
- 9-Day RSI
- 14-Day RSI
- 50-Day SMA
- 6-Month Price Index
- 6-1 Month Momentum %
- 12-1 Month Momentum %

Myovant Sciences Accumulated other comprehensive income (loss)

: $-17.3 Mil (As of Mar. 2022)

View and export this data going back to 2016. Start your Free Trial

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Myovant Sciences's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2022 was $-17.3 Mil.

Myovant Sciences's quarterly Accumulated other comprehensive income (loss) stayed the same from Sep. 2021 ($-17.3 Mil) to Dec. 2021 ($-17.3 Mil) and stayed the same from Dec. 2021 ($-17.3 Mil) to Mar. 2022 ($-17.3 Mil).

Myovant Sciences's annual Accumulated other comprehensive income (loss) declined from Mar. 2020 ($-1.6 Mil) to Mar. 2021 ($-17.3 Mil) but then stayed the same from Mar. 2021 ($-17.3 Mil) to Mar. 2022 ($-17.3 Mil).

Myovant Sciences Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Myovant Sciences's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Accumulated other comprehensive income (loss)

0.02

0.51

-1.65

-17.29

Myovant Sciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Accumulated other comprehensive income (loss)																-17.29	-17.29	-17.29	-17.29	-17.29

Myovant Sciences Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Myovant Sciences Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences Business Description

Industry

Healthcare » Biotechnology NAICS : 541714 SIC : 2834

Comparable Companies

NAS:TGTX SHSE:688076 NAS:GRNA NAS:ARQT BOM:543271 NAS:MRUS NAS:IMAB ASX:IMU NAS:ERAS NYSE:ADCT

Traded in Other Exchanges

71M:Germany

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Potter Myrtle S	director	10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark	director	C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie	director	C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M.	director	ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen	director	C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd.	10 percent owner	27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	60 WALL STREET NEW YORK NY 10005
Seely Lynn	director, officer: Principal Executive Officer	501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi	director	C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank	director	2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

From GuruFocus

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

By Marketwired 02-18-2021

Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022

By GuruFocusNews 01-12-2022

Myovant Sciences to Present at Upcoming Investor Conferences

By Marketwired 02-22-2021

Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress

By Marketwired 10-19-2021

Myovant Sciences Announces European Commission Approval for RYEQO� for the Treatment of Women With Uterine Fibroids

By Marketwired 07-20-2021

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE� for the Management of Moderate to Severe Pain Associated With Endometriosis

By Marketwired 09-09-2021

Enzyvant Receives FDA Approval for RETHYMIC� (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

By Marketwired 10-09-2021

Other Sources

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Mobile App Email Alerts Referral Program Affiliate Program FAQ Contact Us 中文
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

GuruFocus Screeners

My Screeners

Value Screens

Model Portfolios

Market Data

Economic Indicators

By Country

Articles

Submit Articles

Myovant Sciences Accumulated other comprehensive income (loss)

Myovant Sciences Accumulated other comprehensive income (loss) Historical Data

Myovant Sciences Accumulated other comprehensive income (loss) Calculation

Myovant Sciences Accumulated other comprehensive income (loss) Related Terms

Myovant Sciences Business Description

Myovant Sciences Headlines

Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference

Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Nancy Valente, M.D. Joins Myovant Sciences' Board of Directors

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022

Myovant Sciences to Present at Upcoming Investor Conferences

Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress

Myovant Sciences Announces European Commission Approval for RYEQO� for the Treatment of Women With Uterine Fibroids

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE� for the Management of Moderate to Severe Pain Associated With Endometriosis

Enzyvant Receives FDA Approval for RETHYMIC� (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix

$MYOV - Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2020 Results - Earnings Call Transcript.…

Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study

Myovant Sciences (MYOV) Reports Q4 Loss, Tops Revenue Estimates

3 Big Drugmakers Likely to be in Focus in Second Half of 2021

Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More

$MYOV - Myovant Sciences (MYOV) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow.…

Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy

Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates

Myovant Sciences (MYOV) Reports Q3 Loss, Tops Revenue Estimates

$MYOV - Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q2 2021 Results - Earnings Call Transcript.…

Here's Why Pfizer (PFE) Has Been Rallying This Year So Far

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

$MYOV - Myovant: Catalysts Powering More Upside. Myovant Catalysts Powering More Upsides